drugset / Trial / NCT02262572

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

NCT02262572

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)

Timeline

Start
2003-04
Primary completion
2003-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Telmisartan Other / unclassified 80 mg

Indications

No indication recorded.